Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
Tubocurarine chloride is a neuromuscular blocking agent (curare alkaloid) administered by injection for use during anesthesia and surgery. It works by competitively blocking acetylcholine at the neuromuscular junction, causing skeletal muscle paralysis. This drug is a legacy small-molecule agent with a history dating to 1947.
Product is approaching loss of exclusivity with minimal commercial team expansion; career opportunities are limited and primarily defensive in nature.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on tubocurarine chloride offers limited career advancement opportunity, as the product is in late-stage decline with no active clinical pipeline or significant commercial growth. Roles are typically maintenance-focused, supporting institutional sales and regulatory compliance rather than brand building or expansion.
Worked on TUBOCURARINE CHLORIDE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.